Enlivex Therapeutics Ltd. (ENLV) es una empresa que cotiza en bolsa en el Salud sector, operando dentro de la Biotecnología industria. La empresa tiene su sede en Ness Ziona, Israel. El CEO actual es Oren Hershkovitz.
ENLV tiene fecha de IPO 2014-07-31, 71 empleados a tiempo completo, cotiza en el NASDAQ Capital Marke, una capitalización de mercado de $19.93M.
Enlivex Therapeutics Ltd. operates as a clinical-stage macrophage reprogramming immunotherapy company. It is developing Allocetra, a cell-based therapy to treat organ dysfunction and failure associated with sepsis that is in phase II clinical trial, as well as in preclinical trial to treat solid tumors. Enlivex Therapeutics Ltd. was founded in 2005 and is headquartered in Nes Ziona, Israel.
